Patents by Inventor Tilo Schwientek

Tilo Schwientek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220305089
    Abstract: The invention relates to a pharmaceutical composition comprising an isolated Factor VIII protein and/or an isolated VWF protein in a stabilizing buffer composition, wherein said pharmaceutical composition is free of albumin and said stabilizing buffer 5 composition comprises cryoprotectants and bulking agents in a weight ratio of more than 0.65:1. The invention relates further relates to the use of a stabilizing buffer formulating an FVIII protein and/or a VWF protein to the use of a VWF protein for stabilizing a FVIII protein in vitro.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 29, 2022
    Applicant: OCTAPHARMA AG
    Inventors: Ronny SCHMIDT, Tilo SCHWIENTEK
  • Publication number: 20190169268
    Abstract: The invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and said extension peptide comprises a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of the mammalian protein and/or identical or similar to SEQ ID NO: 1. The main protein is preferably VWF. The fusion protein has an increased half life as compared to the main protein and may be used to increase the half-life of a binding partner, e.g. FVIII. The invention further relates to the complex formed by the fusion protein, a polynucleotide encoding the fusion protein as well as a vector and host cell comprising the polynucleotide.
    Type: Application
    Filed: April 26, 2017
    Publication date: June 6, 2019
    Applicant: OCTAPHARMA AG
    Inventors: Christoph KANNICHT, Barbara SOLECKA-WITULSKA, Stefan WINGE, Tilo SCHWIENTEK
  • Patent number: 7381554
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal/Gl cNAc? 1-3GalNAc ??1, 6GlcNAc-transferase, termed C2/4GnT, with unique enzymatic properties is disclosed. The enzymatic activity of C2/4GnT is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2/4GnT and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2/4GnT activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2/4GnT. The enzyme C2/4GnT and C2/4GnT-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2/4GnT.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: June 3, 2008
    Assignee: Glycozym ApS
    Inventors: Henrik Clausen, Tilo Schwientek
  • Patent number: 7097994
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal?1-3GalNAca ?1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: August 29, 2006
    Assignee: Glycozym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Patent number: 7094887
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal?1-3GalNAc? ?1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: August 22, 2006
    Assignee: GlycoZym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Patent number: 7078206
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal?1-3GalNAc? ?1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: July 18, 2006
    Assignee: GlycoZym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Patent number: 6995004
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal/Gl cNAc? 1-3GalNAc ??1, 6GlcNAc-transferase, termed C2/4GnT, with unique enzymatic properties is disclosed. The enzymatic activity of C2/4GnT is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2/4GnT and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2/4GnT activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2/4GnT. The enzyme C2/4GnT and C2/4GnT-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2/4GnT.
    Type: Grant
    Filed: June 4, 2001
    Date of Patent: February 7, 2006
    Assignee: Glycozym ApS
    Inventors: Henrik Clausen, Tilo Schwientek
  • Publication number: 20050042727
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal/Gl cNAc? 1-3GalNAc ??1, 6GlcNAc-transferase, termed C2/4GnT, with unique enzymatic properties is disclosed. The enzymatic activity of C2/4GnT is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2/4GnT and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2/4GnT activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2/4GnT. The enzyme C2/4GnT and C2/4GnT-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2/4GnT.
    Type: Application
    Filed: September 9, 2004
    Publication date: February 24, 2005
    Applicant: Glycozym ApS
    Inventors: Henrik Clausen, Tilo Schwientek
  • Publication number: 20040203092
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3GalNAca &bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Application
    Filed: May 11, 2004
    Publication date: October 14, 2004
    Applicant: Glycozym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Publication number: 20040203111
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3GalNAc&agr;&bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Application
    Filed: May 11, 2004
    Publication date: October 14, 2004
    Applicant: Glycozym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Patent number: 6794169
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3GalNAc&agr; &bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: September 21, 2004
    Assignee: Glycozym ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Patent number: 6635461
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3 GalNAc&agr; &bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: October 21, 2003
    Assignee: Glycozym Aps
    Inventors: Tilo Schwientek, Henrik Clausen
  • Publication number: 20030180778
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3GalNAc&agr; &bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Application
    Filed: March 13, 2003
    Publication date: September 25, 2003
    Applicant: Glycozym APS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Publication number: 20030054525
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal&bgr;1-3GalNAc&agr; &bgr;1,6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The enzymatic activity of C2GnT3 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2GnT3 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2GnT3. The enzyme C2GnT3 and C2GnT3 -active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3.
    Type: Application
    Filed: February 25, 2002
    Publication date: March 20, 2003
    Applicant: GLYCOZYM ApS
    Inventors: Tilo Schwientek, Henrik Clausen
  • Publication number: 20020081656
    Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal/Gl cNAc&bgr; 1-3GalNAc a&bgr;1, 6GlcNAc-transferase, termed C2/4GnT, with unique enzymatic properties is disclosed. The enzymatic activity of C2/4GnT is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding C2/4GnT and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting C2/4GnT activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing C2/4GnT. The enzyme C2/4GnT and C2/4GnT-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2/4GnT.
    Type: Application
    Filed: June 4, 2001
    Publication date: June 27, 2002
    Inventors: Henrik Clausen, Tilo Schwientek